Followers | 37 |
Posts | 4190 |
Boards Moderated | 0 |
Alias Born | 10/18/2016 |
Friday, February 23, 2018 3:56:01 PM
Related Editorial
Modern science has substantiated both the anecdotal history and the efficacy of cannabidiol (“CBD”), a non-psychoactive compound found in the cannabis sativa plant. Research has revealed that CBD may significantly reduce inflammation and is now widely used to treat chronic pain, multiple sclerosis and fibromyalgia, epilepsy, and numerous other conditions. There is even evidence that CBD has potential to prevent symptoms of Alzheimer’s and appears to suppress the growth of cancer cells and promote the death of these cells (http://nnw.fm/S6cXu). While CBD may provide solutions to multiple unmet medical needs, current drug delivery techniques remain antiquated. There are inherent metabolic issues in consistent, effective delivery of cannabinoids, and these new pharmaceutical therapeutics require revolutionary techniques of administration. Establishing a new paradigm in cannabinoid drug delivery, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (PRVCF Profile) is engineering a unique Sol-gel nose-to-brain delivery platform to provide direct, controlled pharmacological drug release. Many large Canadian companies produce cutting-edge pharmaceutical cannabis compounds, yet rely on outdated delivery mechanisms and may find PreveCeutical’s platform superior to current dosing techniques. Some of these companies include Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF), Aphria, Inc. (TSX: APH) (OTCQB: APHQF) and Isodiol International, Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F).
To hear the NetworkNewsAudio version, visit: http://nnw.fm/MAut8
To view the full editorial, visit http://nnw.fm/z62Bc
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information, visit the company’s website at www.PreveCeutical.com.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM